Summary by Body System

| Body System or Organ Class | Placebo | Xanomeline High Dose |
| --- | --- | --- |
| CARDIAC DISORDERS | 10 | 11 |
| EAR AND LABYRINTH DISORDERS | 1 | 1 |
| EYE DISORDERS | 2 | 1 |
| GASTROINTESTINAL DISORDERS | 17 | 18 |
| GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS | 21 | 38 |
| HEPATOBILIARY DISORDERS | 1 | 0 |
| INFECTIONS AND INFESTATIONS | 16 | 13 |
| INJURY, POISONING AND PROCEDURAL COMPLICATIONS | 4 | 5 |
| INVESTIGATIONS | 10 | 6 |
| METABOLISM AND NUTRITION DISORDERS | 5 | 2 |
| MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS | 4 | 7 |
| NERVOUS SYSTEM DISORDERS | 8 | 25 |
| PSYCHIATRIC DISORDERS | 10 | 8 |
| RENAL AND URINARY DISORDERS | 4 | 3 |
| REPRODUCTIVE SYSTEM AND BREAST DISORDERS | 2 | 1 |
| RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS | 8 | 10 |
| SKIN AND SUBCUTANEOUS TISSUE DISORDERS | 19 | 40 |
| SURGICAL AND MEDICAL PROCEDURES | 2 | 2 |
| VASCULAR DISORDERS | 3 | 1 |
| CONGENITAL, FAMILIAL AND GENETIC DISORDERS | 0 | 2 |
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) | 0 | 1 |
| SOCIAL CIRCUMSTANCES | 0 | 1 |

CARDIAC DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ATRIAL FIBRILLATION | 5 | 1 |
| ATRIAL FLUTTER | 2 | 0 |
| ATRIAL HYPERTROPHY | 0 | 2 |
| ATRIOVENTRICULAR BLOCK FIRST DEGREE | 0 | 1 |
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | 0 | 1 |
| BRADYCARDIA | 0 | 4 |
| BUNDLE BRANCH BLOCK RIGHT | 0 | 2 |
| CARDIAC DISORDER | 1 | 0 |
| MYOCARDIAL INFARCTION | 8 | 3 |
| SINUS ARRHYTHMIA | 0 | 2 |
| SINUS BRADYCARDIA | 8 | 1 |
| SUPRAVENTRICULAR EXTRASYSTOLES | 1 | 2 |
| TACHYCARDIA | 0 | 2 |
| VENTRICULAR EXTRASYSTOLES | 1 | 0 |
| VENTRICULAR HYPERTROPHY | 0 | 1 |

CONGENITAL, FAMILIAL AND GENETIC DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| VENTRICULAR SEPTAL DEFECT | 2 | 0 |

EAR AND LABYRINTH DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| EAR PAIN | 0 | 2 |
| VERTIGO | 1 | 0 |

EYE DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| CONJUNCTIVITIS | 0 | 2 |
| EYE ALLERGY | 0 | 1 |
| EYE PRURITUS | 0 | 1 |
| EYE SWELLING | 0 | 1 |
| VISION BLURRED | 2 | 0 |

GASTROINTESTINAL DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ABDOMINAL DISCOMFORT | 1 | 0 |
| ABDOMINAL PAIN | 2 | 1 |
| CONSTIPATION | 0 | 1 |
| DIARRHOEA | 4 | 10 |
| DYSPEPSIA | 0 | 2 |
| FLATULENCE | 0 | 2 |
| GASTROOESOPHAGEAL REFLUX DISEASE | 0 | 1 |
| GLOSSITIS | 0 | 1 |
| HIATUS HERNIA | 0 | 2 |
| NAUSEA | 13 | 3 |
| SALIVARY HYPERSECRETION | 5 | 0 |
| STOMACH DISCOMFORT | 1 | 0 |
| VOMITING | 8 | 3 |

GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| APPLICATION SITE DERMATITIS | 12 | 9 |
| APPLICATION SITE DISCHARGE | 1 | 0 |
| APPLICATION SITE ERYTHEMA | 22 | 3 |
| APPLICATION SITE INDURATION | 0 | 1 |
| APPLICATION SITE IRRITATION | 16 | 7 |
| APPLICATION SITE PAIN | 2 | 0 |
| APPLICATION SITE PERSPIRATION | 3 | 0 |
| APPLICATION SITE PRURITUS | 34 | 10 |
| APPLICATION SITE REACTION | 1 | 2 |
| APPLICATION SITE SWELLING | 3 | 0 |
| APPLICATION SITE URTICARIA | 1 | 0 |
| APPLICATION SITE VESICLES | 5 | 2 |
| ASTHENIA | 1 | 2 |
| CHEST DISCOMFORT | 1 | 0 |
| CHEST PAIN | 2 | 0 |
| CHILLS | 1 | 3 |
| FATIGUE | 5 | 2 |
| FEELING ABNORMAL | 1 | 0 |
| FEELING COLD | 1 | 0 |
| MALAISE | 3 | 0 |
| OEDEMA PERIPHERAL | 3 | 3 |
| PAIN | 1 | 0 |
| PYREXIA | 1 | 2 |

HEPATOBILIARY DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| HYPERBILIRUBINAEMIA | 0 | 1 |

IMMUNE SYSTEM DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |

INFECTIONS AND INFESTATIONS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| BRONCHITIS | 0 | 1 |
| CERVICITIS | 0 | 2 |
| CYSTITIS | 1 | 1 |
| EAR INFECTION | 0 | 4 |
| GASTROENTERITIS VIRAL | 0 | 1 |
| HORDEOLUM | 1 | 0 |
| INFLUENZA | 1 | 2 |
| LOCALISED INFECTION | 0 | 2 |
| LOWER RESPIRATORY TRACT INFECTION | 2 | 0 |
| NASOPHARYNGITIS | 8 | 4 |
| RHINITIS | 1 | 0 |
| UPPER RESPIRATORY TRACT INFECTION | 5 | 12 |
| URINARY TRACT INFECTION | 1 | 4 |
| VAGINAL MYCOSIS | 0 | 2 |

INJURY, POISONING AND PROCEDURAL COMPLICATIONS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| CONTUSION | 3 | 1 |
| EXCORIATION | 1 | 3 |
| FACIAL BONES FRACTURE | 1 | 0 |
| FALL | 1 | 2 |
| HIP FRACTURE | 2 | 2 |
| SKIN LACERATION | 0 | 1 |

INVESTIGATIONS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| BIOPSY | 1 | 0 |
| BIOPSY PROSTATE | 1 | 0 |
| BLOOD ALKALINE PHOSPHATASE INCREASED | 0 | 1 |
| BLOOD CHOLESTEROL INCREASED | 1 | 0 |
| BLOOD CREATINE PHOSPHOKINASE INCREASED | 0 | 2 |
| BLOOD GLUCOSE INCREASED | 2 | 0 |
| BLOOD URINE PRESENT | 0 | 1 |
| CYSTOSCOPY | 0 | 1 |
| ELECTROCARDIOGRAM ST SEGMENT DEPRESSION | 0 | 4 |
| ELECTROCARDIOGRAM T WAVE AMPLITUDE DECREASED | 0 | 1 |
| ELECTROCARDIOGRAM T WAVE INVERSION | 1 | 3 |
| HEART RATE INCREASED | 0 | 2 |
| HEART RATE IRREGULAR | 0 | 4 |
| WEIGHT DECREASED | 2 | 0 |

METABOLISM AND NUTRITION DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| DECREASED APPETITE | 2 | 2 |
| DEHYDRATION | 0 | 1 |
| DIABETES MELLITUS | 0 | 1 |
| FOOD CRAVING | 0 | 1 |
| INCREASED APPETITE | 2 | 2 |

MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ARTHRALGIA | 1 | 1 |
| ARTHRITIS | 1 | 0 |
| BACK PAIN | 4 | 2 |
| FLANK PAIN | 1 | 0 |
| MUSCLE SPASMS | 2 | 0 |
| MYALGIA | 1 | 0 |
| PAIN IN EXTREMITY | 0 | 1 |
| SHOULDER PAIN | 0 | 2 |

NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS)

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| PROSTATE CANCER | 1 | 0 |

NERVOUS SYSTEM DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| AMNESIA | 2 | 0 |
| BURNING SENSATION | 2 | 0 |
| COGNITIVE DISORDER | 1 | 0 |
| DIZZINESS | 15 | 3 |
| HEADACHE | 8 | 3 |
| HYPERSOMNIA | 1 | 0 |
| LETHARGY | 1 | 0 |
| PARAESTHESIA | 1 | 0 |
| PARKINSON'S DISEASE | 0 | 1 |
| PAROSMIA | 2 | 0 |
| PARTIAL SEIZURES WITH SECONDARY GENERALISATION | 1 | 0 |
| PSYCHOMOTOR HYPERACTIVITY | 0 | 1 |
| SOMNOLENCE | 1 | 3 |
| SYNCOPE | 4 | 0 |
| SYNCOPE VASOVAGAL | 1 | 0 |
| TRANSIENT ISCHAEMIC ATTACK | 1 | 0 |

PSYCHIATRIC DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| AGITATION | 1 | 2 |
| COMPLETED SUICIDE | 0 | 1 |
| CONFUSIONAL STATE | 1 | 2 |
| DELIRIUM | 1 | 0 |
| DELUSION | 1 | 1 |
| DISORIENTATION | 0 | 1 |
| HALLUCINATION | 1 | 0 |
| HALLUCINATION, VISUAL | 1 | 0 |
| INSOMNIA | 2 | 3 |
| IRRITABILITY | 0 | 2 |
| LIBIDO DECREASED | 1 | 0 |
| LISTLESS | 1 | 0 |
| NIGHTMARE | 1 | 0 |

RENAL AND URINARY DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| CALCULUS URETHRAL | 1 | 0 |
| DYSURIA | 0 | 1 |
| MICTURITION URGENCY | 2 | 1 |
| NEPHROLITHIASIS | 1 | 1 |
| POLLAKIURIA | 0 | 2 |

REPRODUCTIVE SYSTEM AND BREAST DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| BENIGN PROSTATIC HYPERPLASIA | 1 | 2 |
| PELVIC PAIN | 0 | 2 |

RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ALLERGIC GRANULOMATOUS ANGIITIS | 1 | 0 |
| COUGH | 7 | 1 |
| DYSPNOEA | 1 | 1 |
| EMPHYSEMA | 0 | 1 |
| EPISTAXIS | 2 | 0 |
| HAEMOPTYSIS | 0 | 2 |
| NASAL CONGESTION | 4 | 3 |
| PHARYNGEAL ERYTHEMA | 2 | 0 |
| PHARYNGOLARYNGEAL PAIN | 1 | 0 |
| POSTNASAL DRIP | 0 | 2 |
| PRODUCTIVE COUGH | 1 | 0 |
| RALES | 0 | 2 |
| RESPIRATORY TRACT CONGESTION | 1 | 0 |
| RHINORRHOEA | 2 | 0 |

SKIN AND SUBCUTANEOUS TISSUE DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ACTINIC KERATOSIS | 1 | 0 |
| ALOPECIA | 0 | 1 |
| BLISTER | 2 | 0 |
| COLD SWEAT | 0 | 3 |
| DRUG ERUPTION | 0 | 1 |
| ERYTHEMA | 22 | 11 |
| HYPERHIDROSIS | 10 | 2 |
| PRURITUS | 38 | 11 |
| PRURITUS GENERALISED | 1 | 0 |
| RASH | 15 | 9 |
| RASH MACULO-PAPULAR | 1 | 0 |
| RASH PRURITIC | 3 | 0 |
| SKIN IRRITATION | 8 | 4 |
| SKIN ODOUR ABNORMAL | 1 | 0 |
| SKIN ULCER | 0 | 2 |
| URTICARIA | 2 | 0 |

SOCIAL CIRCUMSTANCES

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ALCOHOL USE | 1 | 0 |

SURGICAL AND MEDICAL PROCEDURES

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| ACROCHORDON EXCISION | 1 | 0 |
| CATARACT OPERATION | 0 | 1 |
| EYE LASER SURGERY | 0 | 1 |
| SKIN LESION EXCISION | 1 | 0 |

VASCULAR DISORDERS

| Reported Term for the Adverse Event | Xanomeline High Dose | Placebo |
| --- | --- | --- |
| HYPERTENSION | 0 | 2 |
| HYPOTENSION | 0 | 3 |
| ORTHOSTATIC HYPOTENSION | 0 | 2 |
| WOUND HAEMORRHAGE | 1 | 0 |